AFM
INDP icon

Anson Funds Management’s Indaptus Therapeutics INDP Stock Holding History

Anson Funds Management’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-22
Closed -$316K – 30
2018
Q1 		$316K Buy
+22
New +$312K 0.24% 23

Other funds holding INDP

ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Anson Funds Management's INDP Position: Q2 2018 in Review

Anson Funds Management sold out of Indaptus Therapeutics (INDP) in Q2 2018, closing a stake of 22 shares — an estimated $316K sold.

Anson Funds Management first reported a position in INDP in Q1 2018 and held it in 1 quarter. The position peaked at $316K in Q1 2018. 26 funds tracked by Wall St. Rank hold INDP as of Q2 2018.

  • Anson Funds Management reported no remaining Indaptus Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Anson Funds Management sold 22 Indaptus Therapeutics shares in Q2 2018, an estimated $316K.
  • Anson Funds Management first reported a position in Indaptus Therapeutics in Q1 2018 and held it in 1 quarter.
  • Anson Funds Management's Indaptus Therapeutics position peaked at $316K in Q1 2018.
  • 26 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q2 2018.

Based on Anson Funds Management's 13F filing for Q2 2018, filed 14 Aug 2018.